Answers are grounded in this paper and cite their sources.
Distributed database analysis shows no increased self-harm risk with GLP-1 receptor agonists in diabetes, suggesting safety.
The use of GLP-1 RAs did not show increased risk of intentional self-harm compared with SGLT-2is or DPP-4is, which provides some reassurance regarding the safety of GLP-1 RA use in patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Kuzucan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: